Ionis Pharmaceuticals IONS Tegsedi — Revenue
Discontinued — last reported Q3 '23
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed November 2, 2023, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's tegsedi — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's tegsedi — revenue?
- Ionis Pharmaceuticals (IONS) reported tegsedi — revenue of $794K in Q3 2023.
- What does tegsedi — revenue mean?
- The total net sales revenue earned from the commercial distribution of the Tegsedi drug product.
- How do you interpret tegsedi — revenue?
- An increase indicates growing market demand, successful commercialization, or expanded patient access for the drug, while a decrease may signal increased competition, patent expirations, or shifts in treatment standards.
- How does tegsedi — revenue compare across companies?
- Comparable to product-specific net revenue metrics reported by other biotechnology firms for their flagship or commercial-stage therapeutic assets.